ReviewInternational journal of molecular sciences2018
Modulation of Apoptosis by Cytotoxic Mediators and Cell-Survival Molecules in Sjögren's Syndrome.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- FASN-mediated metabolic reprogramming drives CD4Arthritis research & therapy · 2026Article
- Autoimmune fibroinflammation in IgG4-related ophthalmic disease: TLR8-dependent signaling pathways and fibrotic remodeling revealed by proteomic profiling.Frontiers in immunology · 2026Article
- Potential Influence of Helicobacter Pylori on Glaucoma-Related Alterations of Ocular Surface Microbiota and Dry Eye Disease Pathophysiology.Investigative ophthalmology & visual science · 2025Article
- Genetic Crosstalk Between Type 1 Diabetes and Sjögren's Syndrome: A Systematic Exploration of Risk Genes and Common Pathways.Journal of cellular and molecular medicine · 2025Article
- ACSS2/AATF Drives Soluble FasL-Mediated CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A comprehensive review of Sjögren's syndrome: Classification criteria, risk factors, and signaling pathways.Heliyon · 2024Review
- Advances in cellular and molecular pathways of salivary gland damage in Sjögren's syndrome.Frontiers in immunology · 2024Review
- Immune and non-immune mediators in the fibrosis pathogenesis of salivary gland in Sjögren's syndrome.Frontiers in immunology · 2024Review
- The role of cytokines from salivary gland epithelial cells in the immunopathology of Sjögren's syndrome.Frontiers in immunology · 2024Review
- Uncovering the Therapeutic Target and Molecular Mechanism of Upadacitinib on Sjogren's Syndrome.Biomedical engineering and computational biology · 2024Article
- Outline of Salivary Gland Pathogenesis of Sjögren's Syndrome and Current Therapeutic Approaches.International journal of molecular sciences · 2023Review
- The Toll-like Receptor 7-Mediated Ro52 Antigen-Presenting Pathway in the Salivary Gland Epithelial Cells of Sjögren's Syndrome.Journal of clinical medicine · 2023Article
- Unsolved mystery of Fas: mononuclear cells may have trouble dying in patients with Sjögren's syndrome.BMC immunology · 2023Article
- Melatonin: a potential therapeutic approach for the management of primary Sjögren's syndrome.Immunologic research · 2023Review
- Molecular Mechanisms Linking Inflammation to Autoimmunity in Sjögren's Syndrome: Identification of New Targets.International journal of molecular sciences · 2022Review
- Integrated Network Pharmacology and Mice Model to Investigate Qing Zao Fang for Treating Sjögren's Syndrome.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Management of Sjögren's Syndrome: Present Issues and Future Perspectives.Frontiers in medicine · 2021Review
- Therapeutic Functions of Stem Cells from Oral Cavity: An Update.International journal of molecular sciences · 2020Review
- Role of Viral Infections in the Pathogenesis of Sjögren's Syndrome: Different Characteristics of Epstein-Barr Virus and HTLV-1.Journal of clinical medicine · 2020Review
- Mechanisms of Disease in Sjögren Syndrome-New Developments and Directions.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis of Sjögren's syndrome (SS) involves multiple factors including genetic background, cell death, and exocrine dysfunction. We here discuss apoptotic control in exocrine glands in SS by showing various pro- and anti-apoptotic pathways. Although the membrane-bound and soluble form of the Fas/Fas ligand system is a leading player with activation of the death domain and caspase 8/3 cleavage, the role of soluble Fas/FasL (including its polymorphism) in apoptosis is controversial. The tumor necrosis factor related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of salivary gland epithelial cells (SGECs) involves a mitochondrial pathway that includes caspase 9 cleavage. The involvement of innate immunity cells such as toll-like receptors (TLRs) has been investigated; TLR2-4 and TLR7-9 are associated with the induction of inflammation in exocrine glands of SS patients. TLR3 has the potential to induce the apoptosis of SS patients' SGECs. Linkage of epidermal growth factor (EGF) was shown in exocrine glands in SS, and it inhibited the Fas/FasL system with the help of cell-survival factors. TLR3 has dual actions to cause inflammation as well as apoptosis, which are inhibited by EGF. In conclusion, apoptosis in exocrine glands of SS patients is tightly controlled by balance of pro-apoptotic signals and growth factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.